Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12,000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.
- Founded June 2007
- 400-500 employees, Cambridge, UK; Lafayette, CO, USA; St Louis, MO, USA; Boyertown, PA, USA
- 148.9 million shares, Freefloat 137.6 million shares (circa. 75% UK 25% US split)
Darrin Disley, Chief Executive Officer; Richard Vellacott, Chief Financial Officer; Ian Gilham, Chairman; Jonathan Milner, Non-Executive Director; Susan Searle, Non-Executive Director; Susan Galbraith, Non-Executive Director; Vishal Gulati, Non-Executive Director; Grahame Cook, Non-Executive Director”